Summary
BeOne Medicines Ltd. (ONC) filed an 8-K on May 14, 2021, primarily related to financial information and the commercial launch of its drug, pamiparib. The company provided historical financial data prepared under China Accounting Standards for Business Enterprises (PRC GAAP) for the years 2017-2019 and the nine months ended September 30, 2020. This data is distinct from U.S. GAAP, with key differences previously summarized in an earlier filing. Supplementary financial information in accordance with U.S. GAAP is also available as Exhibit 99.1 to this report. The most significant operational development announced is the commercial launch of pamiparib in China. Pamiparib is a PARP inhibitor approved for adult patients with recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have a germline BRCA mutation and have undergone at least two prior chemotherapy treatments. The pricing information has been disclosed, indicating a retail price of RMB 7,000 per bottle (60 capsules, 20 mg) or RMB 21,000 for a 30-day supply at the recommended dose. Investors should note that pamiparib is currently not approved for use outside of China.
Key Highlights
- 1Commercial launch of BeOne Medicines' PARP inhibitor, pamiparib, in China for specific ovarian cancer patients.
- 2Pamiparib is indicated for adult patients with recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer with germline BRCA mutations, who have been treated with two or more lines of chemotherapy.
- 3Recommended retail price for pamiparib is RMB 7,000 per bottle (60 capsules; 20 mg), translating to RMB 21,000 for a 30-day supply at the recommended dose.
- 4The filing includes financial information prepared under PRC GAAP for the period ending September 30, 2020, with corresponding U.S. GAAP information provided as Exhibit 99.1.
- 5Key differences between PRC GAAP and U.S. GAAP financial reporting were previously detailed in a January 29, 2021 filing.
- 6The company acknowledges forward-looking statements regarding potential STAR Offering and listing on the STAR Market, contingent upon shareholder approval, market conditions, and regulatory approvals.